Disease landscape

Cholangiocarcinoma clinical trials

Get alerts when Cholangiocarcinoma trials change

518 active trials 296 recruiting 40 Phase 3 280 sponsors 57 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-16

What changed in the last 30 days showing 39 of 57 changes on 20 trials

2026-09-05
Recruitment suspended
Recruitment suspended: Other - evaluation of patients on first stage
NCT06050252 Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine… · National Cancer Institute (NCI) · Phase 2
2026-08-18
Recruitment suspended
Recruitment suspended: Pending protocol amendment
NCT05791448 AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver… · University of Southern California · Phase 1
2026-09-03
Primary completion pushed: 2026-12-01 → 2027-08-31
Completion pushed: 2026-12-01 → 2027-08-31
NCT05506943 A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable… · Compass Therapeutics · Phase 2/3
2026-09-03
Primary completion pushed: 2025-05-15 → 2026-10
Completion pushed: 2025-12 → 2027-03
NCT03440450 A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including… · Fujifilm Pharmaceuticals U.S.A., Inc. · Phase 1
2026-09-10
Primary completion pushed: 2026-01 → 2027-07
Trial status changed: Unknown → Recruiting
Trial sites expanded: 1 → 9 locations
Completion pushed: 2026-07 → 2027-11
NCT06175845 Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma · Universitätsklinikum Hamburg-Eppendorf
2026-08-21
Primary completion pushed: 2026-01-15 → 2027-01-15
Completion pushed: 2026-01-15 → 2027-02-15
NCT06453590 Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or… · Region Stockholm
2026-09-03
Primary completion pushed: 2026-07 → 2027-07
Completion pushed: 2027-07 → 2028-07
NCT06728410 A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced… · Mehmet Akce · Phase 2
2026-08-25
Primary completion pushed: 2026-04 → 2026-12
Enrollment closed, study ongoing
NCT06892925 QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable… · Eastern Hepatobiliary Surgery Hospital · Phase 2
2026-08-18
Primary completion pushed: 2026-07 → 2026-12
NCT06048133 Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced… · Nataliya Uboha · Phase 2
2026-09-01
Primary completion pushed: 2026-06 → 2027-06
Completion pushed: 2026-06 → 2027-06
NCT05497531 Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and… · University of California, Irvine
2026-08-20
Enrollment reduced: 24 → 18 participants
Trial completed
Primary completion moved earlier: 2026-05 → 2025-11-17
Completion moved earlier: 2026-05 → 2025-11-17
NCT05220046 Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced… · University of Nebraska · Phase 1
2026-08-25
Enrollment reduced: 400 → 200 participants
NCT05517811 Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing… · University of Colorado, Denver
2026-09-15
Trial completed
NCT05858736 Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors · OncoC4, Inc. · Phase 1
2026-09-16
Recruitment opened
NCT07619235 A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination… · Xianglin Yuan · Phase 4
2026-08-25
Enrollment reopened
NCT06084481 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With… · AbbVie · Phase 1
2026-09-12
Recruitment opened
NCT07790445 A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic… · Zhai Wenlong · Phase 4
2026-08-26
Enrollment closed, study ongoing
Primary completion moved earlier: 2027-12 → 2026-09
NCT04510740 Liver Cancer Registry Platform · iOMEDICO AG
2026-09-12
Recruitment opened
NCT07714538 Breath Research Narrow Validation for Gastrointestinal Cancer Detection · Imperial College London
2026-09-11
Recruitment opened
Trial sites expanded: 1 → 6 locations
NCT07161869 Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III) · Erasmus Medical Center
2026-09-10
Enrollment closed, study ongoing
Final enrollment: 197 participants (planned 240)
Primary completion moved earlier: 2026-12-31 → 2026-12-01
Completion moved earlier: 2026-12-31 → 2026-12-01
NCT06910670 Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid · Washington University School of Medicine

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-10 NCT07811791 Suprapapillary Versus Transpapillary Plastic Stents for Unresectable Malignant Hilar… National Taiwan University Hospital new
2026-09-10 NCT07812805 SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors SK Life Science, Inc. new Phase 1
2026-09-01 NCT07797816 Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally… The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School new Phase 2
2026-09-01 NCT07796997 GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial… University of Illinois at Chicago new Phase 1
2026-08-26 NCT07786766 Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2… Haitao Zhao, MD new Phase 2
2026-08-24 NCT07780838 Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or… Ohio State University Comprehensive Cancer Center new Phase 2
2026-08-17 NCT07768085 Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT Shengjing Hospital new
2026-08-14 NCT07766187 Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic… University of Wisconsin, Madison new Phase 2
2026-08-14 NCT07765433 Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the… ECOG-ACRIN Cancer Research Group new Phase 2/3
2026-08-12 NCT07760038 Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury Second Affiliated Hospital, Zhejiang University, School of Medicine new

Active trials by phase

Early Phase 1
5
Phase 1
52
Phase 1/2
44
Phase 2
198
Phase 2/3
13
Phase 3
27
Phase 4
10
Not charted: 169 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 518

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07619235 A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination… Xianglin Yuan Recruiting 2026-09-15
NCT07790445 A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic… Zhai Wenlong Recruiting 2026-09-11
NCT07120295 Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories University of Colorado, Denver Recruiting 2026-09-03
NCT07486713 Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Rigel Pharmaceuticals Recruiting 2026-08-11
NCT07405086 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or… OHSU Knight Cancer Institute Recruiting 2026-06-12
NCT07262957 Preventing Postoperative Complications in Patients Undergoing High-risk… Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Recruiting 2025-12-22
NCT05551299 Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic… University of Leipzig Recruiting 2025-03-27
NCT07801027 A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From… Merck Sharp & Dohme LLC Not Yet Recruiting 2026-09-03
NCT07768358 Tucatinib Continuation Study Pfizer Not Yet Recruiting 2026-08-28
NCT06818773 Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer Eastern Hepatobiliary Surgery Hospital Not Yet Recruiting 2025-02-10
Phase 3
NCT05482516 Evaluating Novel Therapies in ctDNA Positive GI Cancers Georgetown University Recruiting 2026-09-14
NCT06282575 Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care… Jazz Pharmaceuticals Recruiting 2026-09-14
NCT07221253 A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of… AstraZeneca Recruiting 2026-08-21
NCT06467357 Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary… AstraZeneca Recruiting 2026-08-19
NCT06622057 D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced… InnoPharmax Inc. Recruiting 2026-07-30
NCT07582315 A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally… Sichuan Baili Pharmaceutical Co., Ltd. Recruiting 2026-07-24
NCT07606599 A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With… Sichuan Baili Pharmaceutical Co., Ltd. Recruiting 2026-07-24
NCT07710885 Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer Taiho Pharmaceutical Co., Ltd. Recruiting 2026-07-17
NCT07265674 A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B)… J-Pharma Co., Ltd. Recruiting 2026-07-01
NCT05615818 Personalized Medicine for Advanced Biliary Cancer Patients UNICANCER Recruiting 2026-05-19
NCT07229625 A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing… Suzhou Suncadia Biopharmaceuticals Co., Ltd. Recruiting 2026-01-28
NCT07155525 Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas Minia University Recruiting 2025-09-18
NCT07062263 Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced… Tata Memorial Centre Recruiting 2025-07-14
NCT05342194 Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of… Shanghai Junshi Bioscience Co., Ltd. Recruiting 2025-04-23
NCT05823311 Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment… Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting 2025-02-10
See all 518 active Cholangiocarcinoma trials with filters →

Top sponsors by active trials in this area

National Cancer Institute (NCI) (17) · Fudan University (14) · Shanghai Zhongshan Hospital (13) · Tianjin Medical University Cancer Institute and Hospital (12) · AstraZeneca (11) · M.D. Anderson Cancer Center (10) · Peking Union Medical College Hospital (10) · Mayo Clinic (8) · Second Affiliated Hospital, School of Medicine, Zhejiang University (7) · Eastern Hepatobiliary Surgery Hospital (6)

Get alerts when Cholangiocarcinoma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free